MAIA Biotechnology Announces $1.51 Million Private Placement

Group 1 - MAIA Biotechnology, Inc. has entered into definitive agreements for the purchase and sale of 1,233,488 shares of common stock at a price of $1.224 per share in a private placement to accredited investors and a Company director [1] - Each share is offered with a warrant to purchase one additional share at an exercise price of $1.36, with the warrants exercisable six months after issuance and valid for three years [1] - The private placement is expected to close on or about December 18, 2025, subject to customary closing conditions [1] Group 2 - The gross proceeds from the offering are expected to be approximately $1.51 million before offering expenses [2] - The net proceeds will be used to fund Step 1 of Part C of the Phase II trial THIO-101 and for working capital [2] Group 3 - The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Securities Act or applicable state securities laws [3] - The warrants and underlying shares may not be offered or sold in the United States except under an effective registration statement or applicable exemption [3] Group 4 - MAIA is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [5]